Cancer Family
Central Nervous System Neoplasm
CI-CAN-00000118Explore in graph →
Non-malignant1,345 active trials7 approved drugs177 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000118Explore in graph →
Clinical trials
5,060 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04915404 | Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | terminated | Phase 1 / Phase 2 | 5 | WPD Pharmaceuticals Sp. z o.o.INDUSTRY | 1 | Jun 6, 2024 | clinicaltrials |
| NCT02085304 | Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM | terminated | Phase 1 / Phase 2 | 8 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Apr 19, 2024 |
| NCT02880410 | Feasibility Study on LITT for Newly Diagnosed Glioblastoma(FLAG) | terminated | Phase 1 | 3 | Monteris MedicalINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02133183 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03705351 | Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | terminated | Phase 1 | 7 | Providence Health & ServicesOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | terminated | Phase 1 / Phase 2 | 26 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05394558 | AsiDNA Children, Adolescents and Young Adults(AsiDNA) | terminated | Phase 1 / Phase 2 | 8 | Institut CurieOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04096716 | Mapping Draining Lymph Nodes in CNS Malignancies | terminated | Phase 1 | 14 | Washington University School of MedicineOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT02168270 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | terminated | Phase 1 | 4 | University of NebraskaOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02530502 | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 4 | Northwestern UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02833701 | Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma | terminated | Phase 1 | 9 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2023 | clinicaltrials |
| NCT02659800 | Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas | terminated | Phase 1 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03971734 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas | terminated | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | terminated | Phase 1 / Phase 2 | 2 | Y-mAbs TherapeuticsINDUSTRY | 5 | Oct 6, 2023 | clinicaltrials |
| NCT04608812 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection | terminated | Phase 1 | 7 | OncoSynergy, Inc.INDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | terminated | Phase 1 | 74 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03267836 | Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma | terminated | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05242146 | GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma(STAR CNS) | terminated | Phase 1 | 12 | GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 6 | Jun 13, 2023 | clinicaltrials |
| NCT03332355 | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 | terminated | Phase 1 | 18 | Vanquish Oncology, Inc.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT01721577 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas(AXL1717) | terminated | Phase 1 / Phase 2 | 10 | Rush University Medical CenterOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03714334 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | terminated | Phase 1 | 16 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT01700569 | Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma(FOLAGLI) | terminated | Phase 1 | 24 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT02664363 | EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma(ExCeL) | terminated | Phase 1 | 3 | Daniel LandiOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT03119064 | BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma(329) | terminated | Phase 1 / Phase 2 | 12 | Brown UniversityOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT04782609 | Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma(Glio) | terminated | Phase 1 | 7 | Samus Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT04489420 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM(CYNK001GBM01) | terminated | Phase 1 | 3 | Celularity IncorporatedINDUSTRY | 1 | Aug 10, 2022 | clinicaltrials |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | terminated | Phase 1 / Phase 2 | 13 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT00479765 | A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma | terminated | Phase 1 / Phase 2 | 4 | Boston Scientific CorporationINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT03711422 | Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | terminated | Phase 1 | 2 | National Cancer Centre, SingaporeOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT02864368 | Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens(PERFORMANCE) | terminated | Phase 1 | 27 | Eric Thompson, M.D.OTHER | 1 | Jun 9, 2022 | clinicaltrials |
| NCT03332589 | E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) | terminated | Phase 1 | 4 | Spirita Oncology, LLCINDUSTRY | 1 | May 20, 2022 | clinicaltrials |
| NCT00669669 | O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas | terminated | Phase 1 / Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02420795 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02687386 | A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR(ECREST) | terminated | Phase 1 | 9 | Dr David ZieglerOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT04073147 | Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma(VENOBI-CNS) | terminated | Phase 1 | 4 | Klinikum StuttgartOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT03422094 | Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | terminated | Phase 1 | 3 | Washington University School of MedicineOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT00633958 | A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors(FLT) | terminated | Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01058850 | Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas | terminated | Phase 1 | 3 | Paul Graham FisherOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT01110876 | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT02046187 | Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma | terminated | Phase 1 / Phase 2 | 14 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT02433392 | Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme. | terminated | Phase 1 | 9 | Boston Scientific CorporationINDUSTRY | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02481960 | Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma(IDEB-glioma) | terminated | Phase 1 / Phase 2 | 5 | Boston Scientific CorporationINDUSTRY | 2 | Apr 21, 2021 | clinicaltrials |
| NCT03050450 | Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors | terminated | Phase 1 | 8 | Johns Hopkins All Children's HospitalOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT03283631 | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM(INTERCEPT) | terminated | Phase 1 | 2 | Gary Archer Ph.D.OTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | terminated | Phase 1 | 35 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | terminated | Phase 1 / Phase 2 | 11 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 5, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2024source: clinicaltrials